US Edition
Published • loading... • Updated
Extra Credit, Not Required: Teva v. Lilly and the Limits of Amgen's Reach
Summary by patentlyo.com
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Extra Credit, Not Required: Teva v. Lilly and the Limits of Amgen's Reach
by Dennis Crouch Since the Supreme Court's 2023 decision in Amgen Inc. v. Sanofi, 598 U.S. 594 (2023), pharmaceutical patentees have been grappling with the heightened disclosure demands for genus claims, particularly in the biologics space where many similar compounds can have similar treatment uses. The Federal Circuit's subsequent application of Amgen in Baxalta Inc. v. Genentech, Inc., 81 F.4th 1362 (Fed. Cir. 2023), reinforced the issues --…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
